Meeting
2013 Genitourinary Cancers Symposium
Prognostic value of free testosterone (FT) levels during salvage chemotherapy with carboplatin plus weekly docetaxel in metastatic castration- and docetaxel-resistant prostate cancer (mDRPC).
Authors
Christoph W. Reuter
Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany
Christoph W. Reuter , Michael A. Morgan , Martin Fenner , Viktor Grünwald , Arnold Ganser
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session A: Prostate Cancer
Track
Prostate Cancer
Sub Track
Prostate Cancer
Citation
J Clin Oncol 31, 2013 (suppl 6; abstr 152)
DOI
10.1200/jco.2013.31.6_suppl.152
Abstract #
152
Poster Bd #
K1
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Prognostic value of free testosterone (FT) levels during chemotherapy with carboplatin plus weekly docetaxel in metastatic castration- and docetaxel-resistant prostate cancer (mDRPC).
First Author: Christoph Reuter
Poster
2016 ASCO Annual Meeting
Prognostic significance of free testosterone levels during chemotherapy with carboplatin plus docetaxel (CD) in metastatic castration- and docetaxel-resistant prostate cancer (mDRPC).
First Author: Christoph W. Reuter
Poster
2014 ASCO Annual Meeting
Prognostic value of free testosterone (FT) levels during salvage chemotherapy with carboplatin plus weekly docetaxel in metastatic castration- and docetaxel-resistant prostate cancer (mDRPC).
First Author: Christoph W. Reuter
Poster
2014 Genitourinary Cancers Symposium
Salvage chemotherapy with carboplatin plus weekly docetaxel in patients (pts) with castration- and docetaxel-resistant prostate cancer (DRPC): Associations of patient and disease characteristics with overall survival (OS).
First Author: Christoph W. Reuter